Legend Biotech Corporation (LEGN)

NASDAQ: LEGN · IEX Real-Time Price · USD
50.92
+1.15 (2.31%)
At close: Dec 2, 2022 4:00 PM
53.55
+2.63 (5.16%)
Pre-market: Dec 5, 2022 6:20 AM EST
2.31%
Market Cap 8.33B
Revenue (ttm) 116.94M
Net Income (ttm) -346.40M
Shares Out 308.70M
EPS (ttm) -2.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 327,420
Open 49.14
Previous Close 49.77
Day's Range 48.81 - 51.53
52-Week Range 30.76 - 57.67
Beta -0.19
Analysts Buy
Price Target 69.36 (+36.2%)
Earnings Date Dec 6, 2022

About LEGN

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candid... [Read more]

Industry Biotechnology
IPO Date Jun 5, 2020
Employees 1,071
Stock Exchange NASDAQ
Ticker Symbol LEGN
Full Company Profile

Financial Performance

In 2021, Legend Biotech's revenue was $89.79 million, an increase of 18.65% compared to the previous year's $75.68 million. Losses were -$386.21 million, 27.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for LEGN stock is "Buy." The 12-month stock price forecast is 69.36, which is an increase of 36.21% from the latest price.

Price Target
$69.36
(36.21% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer

SOMERSET, N.J.--( BUSINESS WIRE )--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-...

1 week ago - Business Wire

Legend Biotech Corporation Sponsored ADR (LEGN) Stock Jumps 14.2%: Will It Continue to Soar?

Legend Biotech Corporation Sponsored ADR (LEGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate ...

1 month ago - Zacks Investment Research

Legend's (LEGN) Q3 Carvykti Preliminary Sales Top Expectations

Legend Biotech (LEGN) reports $55 million as preliminary sales figures for its multiple myeloma therapy in third-quarter 2022. Shares rise 14.2% post the announcement.

1 month ago - Zacks Investment Research

Why Legend Biotech's Shares Jumped 14.2% On Tuesday

The company presented news regarding early revenue figures for a multiple myeloma therapy it collaborated on.

1 month ago - The Motley Fool

CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan's Ministry of Health, Labour and Welfare (MHLW) fo...

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Japan's Ministry of Health, Labour and Welfare (MHLW) has approved CARVYKTI™ for the treatment of adults with relapsed or refractory MM.

2 months ago - Business Wire

Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-th...

2 months ago - Business Wire

Should You Buy Legend Biotech (LEGN) Ahead of Earnings?

Legend Biotech (LEGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

3 months ago - Zacks Investment Research

Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2022

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, biotechnology company developing, manufacturing and commercializing novel therapies to treat life-t...

3 months ago - Business Wire

Legend Biotech Appoints Three New Directors and Elects New Chairman of the Board

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-th...

4 months ago - Business Wire

Legend Biotech Corporation Sponsored ADR (LEGN) Soars 10.9%: Is Further Upside Left in the Stock?

Legend Biotech Corporation Sponsored ADR (LEGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue movi...

4 months ago - Zacks Investment Research

Why Legend Biotech's Shares Jumped 11.8% on Wednesday

Investors, on second glance, might think the company's stock offering is a good idea.

4 months ago - The Motley Fool

Legend Biotech Corporation Announces Pricing of Public Offering

SOMERSET, N.J.--(BUSINESS WIRE)--July 2022 Follow-On Pricing Announcement

4 months ago - Business Wire

Legend Biotech Corporation Announces Proposed Public Offering

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-...

4 months ago - Business Wire

Legend Biotech Shares Move Higher After Bullish BMO Pitch

BMO Capital Markets initiated coverage on Legend Biotech Corporation (NASDAQ: LEGN) with a price target of $77, and an Outperform rating. The analyst says the company's recently approved Carvykti for mu...

5 months ago - Benzinga

Longer-Term Data from CARTITUDE Program Continue to Show Deep and Durable Responses with Ciltacabtagene Autoleucel Ac...

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announces 28-month follow-up data for CARTITUDE-1 and the latest on CARTITUDE 2 cohorts A and B at ASCO 2022 Annual Meeting.

6 months ago - Business Wire

Legend Biotech Announces U.S. FDA Clearance of IND Application for Solid Tumor CAR-T, LB1908 for Relapsed or Refracto...

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announces U.S. FDA clearance of its IND application for solid tumor CAR-T, LB1908.

6 months ago - Business Wire

Legend Biotech Reports First Quarter 2022 Financial Results and Recent Highlights

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-th...

6 months ago - Business Wire

Legend Biotech to Host Investors at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-th...

6 months ago - Business Wire

CARVYKTI® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Pa...

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announced that CARVYKTI has been granted conditional marketing authorization by the European Commission.

6 months ago - Business Wire

Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T...

SOMERSET, N.J.--(BUSINESS WIRE)---- $LEGN--Legend Biotech announced that eight company-sponsored abstracts were accepted at ASCO and EHA 2022.

6 months ago - Business Wire

Legend Biotech Appoints Lori Macomber as Chief Financial Officer

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-th...

6 months ago - Business Wire

Legend Biotech Achieves Milestone Under Collaboration Agreement with Janssen Biotech, Inc. for BCMA CAR-T

SOMERSET, N.J.--(BUSINESS WIRE)--Legend Biotech Achieves Milestone

7 months ago - Business Wire

2 Biotechs With Recent FDA Approvals to Hold for the Next Decade

With trials aimed at increasing addressable markets in the coming years, Legend and Immunocore could reward investors.

Other symbols: IMCR
7 months ago - The Motley Fool